Summarized by Masters of Longevity from PR Newswire.
An article about a biotech company's FDA OK to begin a pivotal prospective clinical study of a new blood-based ovarian cancer screening test, outlining the study’s purpose and regulatory context.
Key Takeaways
- The FDA approved Mercy BioAnalytics' IDE application to start a prospective pivotal SOARA clinical validation study of its screening test.
- The study will evaluate safety of the blood‑based ovarian cancer screening test in average‑risk women using the company's Mercy Halo biomarker platform.
- The test previously received Breakthrough Device Designation but IDE approval does not equal FDA clearance or market approval.
